


Healthcare | Small Cap
Granules India Ltd exhibits a very strong financial profile, marked by exceptional profitability and a secure, low-debt structure. The company is highly effective at turning revenue into profit and generates impressive returns for its investors. Its financial stability is a key strength, as it relies minimally on borrowed funds, making it a low-risk entity in terms of long-term obligations. Furthermore, the company shows outstanding growth potential, with strong projections for future expansion in both revenue and earnings. The primary area of concern is operational efficiency. The company appears to be underutilizing its assets, such as property and inventory, to generate sales. While it is investing heavily in future growth, its current asset management practices show room for improvement. Overall, despite operational inefficiencies, the company's robust profitability, strong growth prospects, and solid financial foundation paint a positive outlook.
Granules India Ltd exhibits a very strong financial profile, marked by exceptional profitability and a secure, low-debt structure. The company is highly effective at turning revenue into profit and generates impressive returns for its investors. Its financial stability is a key strength, as it relies minimally on borrowed funds, making it a low-risk entity in terms of long-term obligations. Furthermore, the company shows outstanding growth potential, with strong projections for future expansion in both revenue and earnings. The primary area of concern is operational efficiency. The company appears to be underutilizing its assets, such as property and inventory, to generate sales. While it is investing heavily in future growth, its current asset management practices show room for improvement. Overall, despite operational inefficiencies, the company's robust profitability, strong growth prospects, and solid financial foundation paint a positive outlook.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
52.26
Industry Median
16.70
Small Cap Median
16.25
P/E RATIO
35.20
P/B RATIO
4.12
Industry Median
2.20
Small Cap Median
2.20
P/S RATIO
3.91
Industry Median
1.40
Small Cap Median
1.40
Others
PEG RATIO
19.03
EV/EBITDA RATIO
17.14
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹845.1 as on Aug 5, 2026.
The company demonstrates an exceptional outlook for growth across all key areas. Despite some recent volatility, the underlying trend and future projections point to a period of strong expansion. This includes significant anticipated increases in revenue, operating profit, and net income. The company is also expected to grow its asset base, indicating a clear strategy for reinvestment and expansion. This robust growth profile is a major strength and a primary driver of future value.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 16.28 | 19.84 | -0.13 | -0.53 | 19.72 |
| Operating Profit Growth Rate | -15.07 | 25.86 | -6.23 | 10.49 | 25 |
| Earnings Per Share (EPS) Growth | -24.98 | 28.25 | -21.65 | 23.68 | 16.1 |
| Asset Growth Rate | 21.52 | 8.67 | 12.14 | 13.15 | 24.1 |
| Net Income Growth Rate | -24.77 | 25.18 | -21.66 | 23.95 | 18.53 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Granules India Ltd | 7.73 | 34.93 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 2 | FDC Ltd | 7.64 | 21.40 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Alembic Pharmaceuticals Ltd | 7.60 | 24.31 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 4 | Supriya Lifescience Ltd | 7.46 | 34.29 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 5 | Aarti Pharmalabs Ltd | 7.46 | 35.92 | Neutral | 369.00 | 19.43 | 175.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 40.87 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Marksans Pharma Ltd | 7.24 | 29.16 | Neutral | 601.00 | 6.64 | 420.00 |
| 8 | Shilpa Medicare Ltd | 5.94 | 59.39 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 9 | Jubilant Pharmova Ltd | 5.71 | 37.02 | Neutral | 1260.00 | 1.25 | 398.00 |
| 10 | Natco Pharma Ltd | 5.69 | 11.52 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 11 | Strides Pharma Science Ltd | 5.55 | 16.53 | Undervalued | 925.00 | 19.92 | 575.00 |
| 12 | Jeena Sikho Lifecare Ltd | 5.52 | 33.85 | Neutral | 349.00 | 17.87 | 222.00 |
| 13 | Wockhardt Ltd | 5.07 | 150.65 | Neutral | 652.00 | 19.51 | 199.00 |
| 14 | Sequent Scientific Ltd | 4.61 | 313.39 | Overvalued | 162.00 | 1.74 | 32.00 |
| 15 | Procter & Gamble Health Ltd | 3.45 | 30.81 | Neutral | 457.00 | 196.94 | 327.00 |
| 16 | Sanofi India Ltd | 3.45 | 18.66 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤5th May 26
Q4 & FY26 Earnings Conference Call
BULLISH SENTIMENT
Quarterly Report⬤23rd Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT